PIPELINE
EP282 - FFAR2
EPICS’ EP282 – FFAR2: Ready to advance into Phase II clinical development, targeting the microbiome–immune axis to treat autoimmune disease.
Not a fecal transplant. Not a live bacterial therapy.
A precise, controllable molecule that boosts a natural microbial signal the body depends on.
EPICS Therapeutics is developing EP282, a first-in-class small molecule that activates FFAR2.
Rather than introducing microbes or trying to reshape the microbiome directly, EP282 activates a natural signaling pathway at the core of gut–immune communication that normally depends on microbial signals received by FFAR2.
By restoring this mechanism, EPICS’ FFAR2 agonist offers a novel approach to treating autoimmune and inflammatory diseases.
EP282 is ready for Phase II clinical development, with an initial therapeutic focus on diseases marked by disrupted microbiome–immune signaling, such as ulcerative colitis, and C. difficile infection.
EP282 is supported by broad patent protection, ensuring long-term exclusivity.
The gut–microbiome–immune axis
The intestinal tract is a remarkably sophisticated immune barrier, absorbing nutrients while keeping pathogens and toxins out of the bloodstream. This protection depends on a finely tuned relationship with the gut microbiome. Microbes produce short-chain fatty acids (SCFAs) that guide immune cells, strengthen the gut’s protective lining, and help maintain a stable, resilient environment.
EP282
What is FFAR2 and why it matters
FFAR2 (Free Fatty Acid Receptor 2) is one of the body’s key sensors for short-chain fatty acids (SCFAs). Through this pathway, FFAR2 helps the immune system:
- distinguish between harmless commensals and potential pathogens
- support the growth of immune cells that help repair the gut lining (IL-22–producing ILC3s)
- sustain antimicrobial defenses
- preserve barrier integrity and overall immune balance
A substantial body of scientific literature links intestinal dysbiosis with the etiology of autoimmune diseases such as ulcerative colitis and over time, an increased vulnerability to colorectal cancer.
“EP282 acts as a potent FFAR2 agonist, boosting the SCFA-driven signaling that promotes gut immune balance under healthy conditions. By activating this natural pathway, EP282 helps compensate for the loss of microbial cues seen in dysbiosis.”
EP282
The science behind EP282’s precision
EP282 uses targeted, receptor-level activation to restore the immune signaling that breaks down during dysbiosis. Instead of relying on microbial metabolites (which are low in potency, vary widely between individuals, and are contingent upon the dynamics of the microbiota), EP282 delivers a consistent and highly selective stimulus to FFAR2, the receptor that links microbial cues to gut immune balance.
This design gives EP282 several advantages over existing microbiome-based approaches:
● A clear mechanism of action
● once-daily oral administration
● high–potency activation of FFAR2
● exceptional selectivity, limiting off-target effects
● a safety profile supportive of long–term, chronic use
● the predictability and scalability of a small molecule, an advantage over the limitations of fecal transplants or live bacterial therapies
Rather than trying to repopulate or reshape the microbiome, EPICS’ EP282 activates the body’s own homeostatic pathways, delivering a consistent, predictable signal to restore gut–immune harmony in autoimmune and inflammation-driven diseases.
Clinical development status
A completed Phase 1 study has demonstrated that EP282 is safe, well tolerated, and supported by validated blood biomarkers indicating a clinically active dose. These results provide strong translational confidence and clear guidance for Phase II trial design.
“EP282 also exemplifies a paradigm shift in oncology: moving from directly targeting cancer cells to modulating metabolic and microbiota–driven pathways.”
Opportunities in oncology
EP282’s FFAR2 signaling also intersects meaningfully with cancer biology through:
- Microbiota imbalance: Disruption of gut microbial diversity, leading to compromised barrier function and chronic inflammation.
- Immune dysfunction: Increased neutrophil infiltration and T-cell exhaustion.
In turn, EPICS’ preclinical studies demonstrate that FFAR2 agonists delay the progression of colonic polyps to adenomas and carcinoma, highlighting their potential in colorectal cancer treatment and in preventing disease progression in Familial Adenomatous Polyposis (FAP).
Moreover, cancer therapies—particularly chemotherapy and immune checkpoint inhibitors—can induce the adverse events of severe gut inflammation and dysbiosis, which exacerbate mucosal damage, worsen inflammation, and delay recovery.
Addition of EP282 to standard-of-care (‘SoC’) cancer therapies may:
- Reduce SoC treatment-related colitis
- Improve patient tolerance
- Overcome resistance
- Support a more favorable immune environment for anti-tumor activity
